Rina-S
rinatabart sesutecan
PHASE3
Drug Profile
ModalityADC
RouteIV
Therapy AreaOncology
Peak Sales Est$1500M
Formulations[]
Mechanism: Tissue factor-targeting ADC (Rina-S)
Expert: Next-generation TF-targeting ADC with topoisomerase I inhibitor payload for endometrial and other solid tumors.
Everyday: A targeted drug that delivers a powerful cancer-killing payload to tumors.
Targets: ["TF"]
Programs (1)
| Indication | Stage | Key Study | Regional Status |
|---|
| Adv EC | PHASE3 | RING-301 | [] |
Upcoming Catalysts (2)
Rina-S - PROC - Ph2 - Data Update (RAINFOL-01)
H2 2026
Rina-S - PROC - Accelerated Approval Filing
Q1 2027
Notes
Partnership with ProfoundBio. Breakthrough therapy designation for advanced endometrial cancer. Next-gen TF-targeting ADC with topo I payload. Differentiated from Tivdak.
Data from Supabase · Updated 2026-03-24